mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

NCT06919796 | Not Yet Recruiting Phase 2 FDA Drug

• 1 other identifier: COVID-PJ-01
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe

Conditions

Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers; SARS CoV-2

Keywords

Tropis ID; Needle-free injection; Tropis

Outcome Measures

Primary Outcomes (1)

• Primary Objective

  In 40 participants response rate, and magnitude of SARS-CoV-2-specific antibody neutralization titers will be measured at Day 30 and Month 6-9 after vaccination

  Nine months

Secondary Outcomes (1)

• Secondary Objective

  Nine months

Study Arms (2)

mRNA vaccine administration via Tropis ID NFIS

EXPERIMENTAL

Immunization with a single dose of mRNA Covid-19 vaccine administered intradermally using the Tropis Needle Free Injection System

Biological: COMIRNATY®

Intramuscular injection of the mRNA Covid-19 vaccine via needle and syringe

ACTIVE COMPARATOR

Immunization with a single dose of mRNA Covid-19 vaccine administered intramuscularly using needle and syringe

Biological: COMIRNATY®

Interventions

COMIRNATY® BIOLOGICAL

COVID-19 Vaccine, mRNA suspension

Intramuscular injection of the mRNA Covid-19 vaccine via needle and syringe; mRNA vaccine administration via Tropis ID NFIS

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able to understand and give informed consent
• Adults aged 18 to 50 years old.
• Willing and able to comply with all scheduled visits, vaccination, and laboratory tests.
• Determined by investigator to be in good health based on medical history, targeted physical exam and laboratory testing.
• Participants with pre-existing stable chronic medical conditions defined as condition not requiring significant change in therapy or hospitalization for worsening disease within 4 weeks from enrollment, can be included at the discretion of the investigator.
• For women of childbearing potential: willing to engage in effective methods of contraception starting at least 30 days prior to enrollment and for the duration of the study.

You may not qualify if:

• Receipt of blood products 90 days prior to study entry and for the duration of the study.
• Volunteers who donated blood 60 days before screening OR will donate blood on or before D30.
• Receipt of any experimental agents within 30 days or 5 half-lives whichever is longer prior to vaccination and for the duration of the study.
• Receipt of any licensed vaccine within 60 days prior to study vaccination or planned receipt of any vaccine until 60 days later as well as receipt of COVID-19 vaccine for the duration of the study.
• Receipt of a COVID-19 vaccine or confirmed COVID-19 in the past year or positive SARS-CoV-2 antigen test on vaccination day.
• Chronic medical problems including (but not limited to) autoimmune disease, severe gastrointestinal disease, and grade 4 hypertension.
• Any diseases or conditions that put individuals at increased risk for severe COVID-19 illness, including: type 1 or 2 diabetes, chronic lung disease (including moderate to severe asthma, bronchiectasis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease (COPD), interstitial lung disease including idiopathic pulmonary fibrosis, pulmonary embolism, or pulmonary hypertension), cystic fibrosis, dementia, Parkinson's disease, cerebrovascular disease, chronic liver disease, chronic kidney disease (any stage), heart conditions, hemoglobin blood disorders (sickle cell disease, thalassemia).
• BMI \> 40 kg/m2
• Any potentially immune mediated disease (with the exception of well controlled hypothyroidism).
• Alcohol or drug abuse and psychiatric conditions that in the opinion of the investigator would preclude compliance with the trial or interpretation of safety or endpoint data.
• Impaired immune function or chronic infections including (but not limited to) HIV, hepatitis B or C; organ transplant; active cancer or any history of hematologic cancer; receipt of chemotherapy, radiation therapy (past 12 months) or any other potentially immunosuppressive therapy \[i.e. received oral, intramuscular or intravenous systemic immunosuppressants, or immune modifying drugs for \>14 days in total within 6 months prior to any study vaccine dose (for corticosteroids ≥ 20 mg/day of prednisone equivalent). Note: Topical medications are allowed.\], congenital immunodeficiency, anatomical or functional asplenia.
• Pregnancy or breast feeding or planned pregnancy for the duration of the study.
• Severe reactions to prior vaccination with Covid-19 mRNA vaccine or any of its components, including anaphylaxis.
• History of Guillain Barré syndrome or myopericarditis.
• Volunteers with any acute illness, including any fever (\> 100.4 F \[\> 38.0C\], regardless of the route) within 3 days prior to study entry.

Sponsors & Collaborators

• PharmaJet, Inc.: lead
• Emory University: collaborator

Study Sites (1)

Hope Clinic of the Emory Vaccine Center Division of Infectious Diseases, Department of Medicine, School of Medicine

Decatur, Georgia, 30030, United States

Location

MeSH Terms

Interventions

BNT162 Vaccine

Intervention Hierarchy (Ancestors)

mRNA Vaccines; Nucleic Acid-Based Vaccines; Vaccines, Synthetic; Recombinant Proteins; Proteins; Amino Acids, Peptides, and Proteins; Vaccines; Biological Products; Complex Mixtures; COVID-19 Vaccines; Viral Vaccines; Antigens; Biological Factors

Central Study Contacts

Nadine Rouphael, MD

CONTACT

404-712-1435; nroupha@emory.edu

Sonia Wimalasena

CONTACT

sonia.tandon@emory.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 3, 2025
• First Posted: April 9, 2025
• Study Start: May 1, 2025
• Primary Completion: May 1, 2026
• Study Completion (Estimated): November 25, 2026
• Last Updated: April 15, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)